Literature DB >> 15844826

Antibodies: an alternative for antibiotics?

L R Berghman1, D Abi-Ghanem, S D Waghela, S C Ricke.   

Abstract

In 1967, the success of vaccination programs, combined with the seemingly unstoppable triumph of antibiotics, prompted the US Surgeon General to declare that "it was time to close the books on infectious diseases." We now know that the prediction was overly optimistic and that the fight against infectious diseases is here to stay. During the last 20 yr, infectious diseases have indeed made a staggering comeback for a variety of reasons, including resistance against existing antibiotics. As a consequence, several alternatives to antibiotics are currently being considered or reconsidered. Passive immunization (i.e., the administration of more or less pathogen-specific antibodies to the patient) prior to or after exposure to the disease-causing agent is one of those alternative strategies that was almost entirely abandoned with the introduction of chemical antibiotics but that is now gaining interest again. This review will discuss the early successes and limitations of passive immunization, formerly referred to as "serum therapy," the current use of antibody administration for prophylaxis or treatment of infectious diseases in agriculture, and, finally, recent developments in the field of antibody engineering and "molecular farming" of antibodies in various expression systems. Especially the potential of producing therapeutic antibodies in crops that are routine dietary components of farm animals, such as corn and soy beans, seems to hold promise for future application in the fight against infectious diseases.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15844826      PMCID: PMC7107177          DOI: 10.1093/ps/84.4.660

Source DB:  PubMed          Journal:  Poult Sci        ISSN: 0032-5791            Impact factor:   3.352


  62 in total

Review 1.  Immune therapy for infectious diseases at the dawn of the 21st century: the past, present and future role of antibody therapy, therapeutic vaccination and biological response modifiers.

Authors:  U K Buchwald; L Pirofski
Journal:  Curr Pharm Des       Date:  2003       Impact factor: 3.116

2.  Behring's discovery of diphtheria and tetanus antitoxins.

Authors:  F J Grundbacher
Journal:  Immunol Today       Date:  1992-05

3.  Production of antibodies in transgenic plants.

Authors:  A Hiatt; R Cafferkey; K Bowdish
Journal:  Nature       Date:  1989-11-02       Impact factor: 49.962

Review 4.  Peroral immunotherapy with yolk antibodies for the prevention and treatment of enteric infections.

Authors:  D Carlander; H Kollberg; P E Wejåker; A Larsson
Journal:  Immunol Res       Date:  2000       Impact factor: 2.829

5.  Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli.

Authors:  J S Huston; D Levinson; M Mudgett-Hunter; M S Tai; J Novotný; M N Margolies; R J Ridge; R E Bruccoleri; E Haber; R Crea
Journal:  Proc Natl Acad Sci U S A       Date:  1988-08       Impact factor: 11.205

Review 6.  Oral delivery of antibodies. Future pharmacokinetic trends.

Authors:  R M Reilly; R Domingo; J Sandhu
Journal:  Clin Pharmacokinet       Date:  1997-04       Impact factor: 6.447

Review 7.  Benefits and risks of antibody and vaccine production in transgenic plants.

Authors:  Heribert Warzecha; Hugh S Mason
Journal:  J Plant Physiol       Date:  2003-07       Impact factor: 3.549

8.  Protection of neonatal calves against fatal enteric colibacillosis by administration of egg yolk powder from hens immunized with K99-piliated enterotoxigenic Escherichia coli.

Authors:  Y Ikemori; M Kuroki; R C Peralta; H Yokoyama; Y Kodama
Journal:  Am J Vet Res       Date:  1992-11       Impact factor: 1.156

9.  Passive protection against bovine rotavirus in calves by specific immunoglobulins from chicken egg yolk.

Authors:  M Kuroki; M Ohta; Y Ikemori; R C Peralta; H Yokoyama; Y Kodama
Journal:  Arch Virol       Date:  1994       Impact factor: 2.574

10.  Rattlesnake and scorpion antivenoms from the egg yolks of immunized hens.

Authors:  B S Thalley; S B Carroll
Journal:  Biotechnology (N Y)       Date:  1990-10
View more
  8 in total

Review 1.  Recombinant IgA production for mucosal passive immunization, advancing beyond the hurdles.

Authors:  Vikram Virdi; Paloma Juarez; Veronique Boudolf; Ann Depicker
Journal:  Cell Mol Life Sci       Date:  2015-10-28       Impact factor: 9.261

2.  Targeting pili in enterococcal pathogenesis.

Authors:  Kenneth L Pinkston; Kavindra V Singh; Peng Gao; Nathaniel Wilganowski; Holly Robinson; Sukhen Ghosh; Ali Azhdarinia; Eva M Sevick-Muraca; Barbara E Murray; Barrett R Harvey
Journal:  Infect Immun       Date:  2014-01-22       Impact factor: 3.441

Review 3.  Effects of Traditional Chinese Medicine and its Active Ingredients on Drug-Resistant Bacteria.

Authors:  Jimin Li; Shanshan Feng; Xin Liu; Xu Jia; Fengling Qiao; Jinlin Guo; Shanshan Deng
Journal:  Front Pharmacol       Date:  2022-06-02       Impact factor: 5.988

4.  Healthy humans can be a source of antibodies countering COVID-19.

Authors:  Nileena Velappan; Hau B Nguyen; Sofiya Micheva-Viteva; Daniel Bedinger; Chunyan Ye; Betty Mangadu; Austin J Watts; Robert Meagher; Steven Bradfute; Bin Hu; Geoffrey S Waldo; Antonietta M Lillo
Journal:  Bioengineered       Date:  2022-05       Impact factor: 6.832

5.  In vitro reactivity and growth inhibition of EPEC serotype O111 and STEC serotypes O111 and O157 by homologous and heterologous chicken egg yolk antibody.

Authors:  José Araujo Amaral; Milene Tino De Franco; Lucy Zapata-Quintanilla; Solange Barros Carbonare
Journal:  Vet Res Commun       Date:  2007-12-11       Impact factor: 2.459

Review 6.  Developments in Rapid Detection Methods for the Detection of Foodborne Campylobacter in the United States.

Authors:  Steven C Ricke; Kristina M Feye; W Evan Chaney; Zhaohao Shi; Hilary Pavlidis; Yichao Yang
Journal:  Front Microbiol       Date:  2019-01-23       Impact factor: 5.640

7.  Conjugation of Different Immunogenic Enterococcal Vaccine Target Antigens Leads to Extended Strain Coverage.

Authors:  F Romero-Saavedra; D Laverde; E Kalfopoulou; C Martini; R Torelli; D Martinez-Matamoros; M Sanguinetti; J Huebner
Journal:  J Infect Dis       Date:  2019-10-08       Impact factor: 5.226

8.  An Old Solution for a New Problem: Antiserum against Emerging Infectious Diseases.

Authors:  Victor Morais
Journal:  Front Public Health       Date:  2016-08-26
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.